JMDC, Gene Techno Science, Astellas Venture Management and Nissay Capital have contributed to a $25.8m round for Keio University's heart failure treatment developer.
Heartseed, a Japan-based developer of treatments for heart failure (HF) based on research at Keio University, has secured ¥2.8bn ($25.8m) in series B funding from investors including medical data technology provider JMDC.
Biopharmaceutical firm Gene Techno Science also took part, as did Astellas Venture Management, Nissay Capital, SBI Investment and SMBC Capital – respective subsidiaries of pharmaceutical firm Astellas, insurer Nippon Life and financial services firms SBI and Sumitomo Mitsui Banking Corporation.
Founded in 2015, Heartseed is developing…
